Indivior PLC (NASDAQ:INDV) Given Average Rating of “Buy” by Analysts

Indivior PLC (NASDAQ:INDV) has received an average rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $39.3333.

A number of equities research analysts have issued reports on INDV shares. Weiss Ratings lowered Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th.

Indivior Price Performance

Shares of NASDAQ INDV opened at $38.13 on Friday. The firm has a fifty day moving average price of $35.28 and a 200-day moving average price of $34.27. The stock has a market cap of $4.65 billion, a PE ratio of 19.55 and a beta of 0.88. Indivior has a 1 year low of $13.45 and a 1 year high of $41.00.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. The firm had revenue of $317.00 million during the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. On average, research analysts expect that Indivior will post 4.05 EPS for the current year.

Insider Activity

In related news, CFO Ryan Preblick sold 36,000 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the sale, the chief financial officer owned 284,751 shares in the company, valued at approximately $10,735,112.70. This trade represents a 11.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

Institutional investors have recently added to or reduced their stakes in the stock. Salomon & Ludwin LLC purchased a new stake in Indivior during the 4th quarter valued at approximately $30,000. Harbor Capital Advisors Inc. grew its stake in Indivior by 309.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after acquiring an additional 781 shares in the last quarter. Quarry LP purchased a new position in Indivior during the third quarter valued at $26,000. Caitong International Asset Management Co. Ltd grew its stake in Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after acquiring an additional 460 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Indivior by 544.6% during the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after purchasing an additional 1,013 shares in the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.